- Stocks
- Pharma & Healthcare
- Strides Pharma Science
Strides Pharma Science share price
NSE: STARPharma & HealthcareDrug Manufacturers - Specialty & Generic
Strides Pharma Science at a glance
Strides Pharma Science (NSE: STAR) closed at ₹1,017.30 on 22 Oct 2026, down 1.23% on the day. With a market capitalisation of ₹9,377 Cr, it ranks 573rd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 16.9× trailing earnings, against a return on equity of 17.9% in FY26. Over the past year the share price has risen 27.8%. Its 52-week range is ₹768.65 (29 Jan 2026) to ₹1,260.90 (21 Sep 2026); the last close is 19.3% below the high. Promoters held 27.91% of the company as of 30 Jun 2026; 38.10% of promoter shares were pledged.
Key numbers
- Market cap
- ₹9,377 CrRank 573 on NSE
- P/E (trailing)
- 16.9×
- Price to book
- 2.78×FY26
- ROE
- 17.9%FY26
- ROCE
- 21.7%FY26
- Debt to equity
- 0.54FY26
- Net profit margin
- 11.8%FY26
- Book value / share
- ₹337.14FY26
- 52-week high
- ₹1,260.9021 Sep 2026
- 52-week low
- ₹768.6529 Jan 2026
- 1-year return
- +27.8%
- RSI (14-day)
- 33.6
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −1.23% | −5.5% | −17.1% | −2.4% | +27.8% |
Strides Pharma Science financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹3,316 Cr | ₹3,070 Cr | ₹3,688 Cr | ₹4,051 Cr | ₹4,565 Cr | — |
| Operating profit | ₹330 Cr | −₹298 Cr | ₹16 Cr | ₹248 Cr | ₹420 Cr | — |
| Net profit | ₹356 Cr | −₹363 Cr | ₹73 Cr | ₹81 Cr | ₹3,596 Cr | — |
| EPS (₹) | ₹30.00 | −₹51.00 | −₹22.00 | −₹8.00 | ₹391.00 | — |
| Cash from operations | ₹481 Cr | −₹258 Cr | ₹44 Cr | ₹701 Cr | ₹684 Cr | — |
| Total debt | ₹883 Cr | ₹836 Cr | ₹1,140 Cr | ₹672 Cr | ₹571 Cr | ₹552 Cr |
| Shareholders' equity | ₹2,777 Cr | ₹2,359 Cr | ₹2,195 Cr | ₹2,126 Cr | ₹2,552 Cr | ₹3,108 Cr |
Strides Pharma Science shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 28.30% | 28.30% | 27.86% | 27.86% | 27.91% | 27.91% |
| Foreign institutions | 28.32% | 28.02% | 28.51% | 29.52% | 28.68% | 28.39% |
| Domestic institutions | 13.72% | 13.30% | 12.98% | 13.02% | 14.45% | 15.41% |
| Non-institutions | 29.65% | 30.37% | 30.64% | 29.59% | 28.95% | 28.28% |
| Promoter shares pledged | 51.98% | 50.10% | 44.13% | 30.60% | 27.27% | 38.10% |
Strides Pharma Science vs peers
The listed Pharma & Healthcare companies nearest to Strides Pharma Science by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| AKUMSAkums Drugs and Pharmaceuticals | ₹690.85 | −0.17% | +50.2% | ₹10,874 Cr | 41.5 | — |
| PARKHOSPSPark Medi World | ₹220.45 | −0.74% | — | ₹9,522 Cr | 32.1 | — |
| BLUEJETBlue Jet Healthcare | ₹499.60 | +1.50% | −23.8% | ₹9,456 Cr | 35 | — |
| VIYASHViyash Scientific | ₹214.90 | −0.05% | +3.1% | ₹9,388 Cr | 53.6 | — |
| STARStrides Pharma Science | ₹1,017.30 | −1.23% | +27.8% | ₹9,377 Cr | 16.9 | — |
| YATHARTHYatharth Hospital & Trauma Care Services | ₹932.10 | +1.22% | +14.4% | ₹8,981 Cr | 51.2 | — |
| HCGHealthcare Global Enterprises | ₹552.00 | +0.60% | −19.8% | ₹8,241 Cr | — | — |
Ask anything about Strides Pharma Science
Pivot answers on the live chart with evidence you can check, and tests strategies against STAR's own history. Try: “Why has STAR moved over the last three months?” · “Backtest a 50-day moving-average crossover on STAR over five years” · “Compare STAR with AKUMS on margins and valuation”
Frequently asked questions about Strides Pharma Science
What is the share price of Strides Pharma Science today?
Strides Pharma Science (NSE: STAR) last closed at ₹1,017.30 on 22 Oct 2026. Its 52-week high is ₹1,260.90 and its 52-week low is ₹768.65.
What is the market cap of Strides Pharma Science?
Strides Pharma Science's market capitalisation is ₹9,377 Cr (₹9,377 Cr) at the 22 Oct 2026 close, ranking 573rd among the NSE companies Pivot tracks.
What is the P/E ratio of Strides Pharma Science?
Strides Pharma Science trades at a trailing P/E of 16.9. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 41.5.
What is the ROE and ROCE of Strides Pharma Science?
Return on equity was 17.9% in FY26 and return on capital employed was 21.7% in FY26 (consolidated figures).
Is Strides Pharma Science a debt-free company?
No. Strides Pharma Science's debt-to-equity ratio was 0.54 in FY26, with total debt of ₹552 Cr.
How has Strides Pharma Science stock performed over the last year?
Strides Pharma Science's share price has risen 27.8% over the past year, −2.4% over three months and −17.1% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Strides Pharma Science?
As of 30 Jun 2026: promoters 27.91%, foreign institutions 28.39%, domestic institutions 15.41%, non-institutions 28.28%. 38.10% of promoter shares were pledged.
Who are Strides Pharma Science's competitors?
The listed Pharma & Healthcare companies closest to Strides Pharma Science by market cap are Akums Drugs and Pharmaceuticals, Park Medi World, Blue Jet Healthcare, Viyash Scientific, Yatharth Hospital & Trauma Care Services and Healthcare Global Enterprises.
Is Strides Pharma Science a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Strides Pharma Science's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on STAR against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with S · all NSE stocks · this page as text